◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 2487

Cutia Therapeutics (2487) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-11

Cutia Therapeutics (2487) operates in the Biotechnology industry and is headquartered in Shanghai, China with about 304 employees. Its market capitalization is roughly CNY 843 million. In the fiscal year ended 2025-12-31, 2487 reported CNY 336M in revenue and (CNY 340M) in net income.

Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People's Republic of China and Hong Kong.

Interactive charts & full statements →

2487 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total RevenueCNY 336MCNY 280MCNY 138MCNY 11M
Gross ProfitCNY 196MCNY 144MCNY 71MCNY 8M
Operating Income (EBIT)(CNY 291M)(CNY 455M)(CNY 527M)(CNY 303M)
Net Income(CNY 340M)(CNY 434M)(CNY 2.0B)(CNY 556M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2487 Free Cash Flow History

2487 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 1.3BCNY 1.4BCNY 1.7BCNY 1.4B
Total LiabilitiesCNY 421MCNY 418MCNY 358MCNY 2.7B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2487 viewer.

Other Companies in Biotechnology

← 2486All “0-9” companies2488 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.